News from avidity biosciences, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 17, 2021, 16:05 ET Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jan 21, 2021, 08:30 ET Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jan 11, 2021, 08:30 ET Avidity Biosciences Announces Changes to its Board of Directors

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jan 08, 2021, 08:30 ET Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Dec 22, 2020, 16:05 ET Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Dec 21, 2020, 16:05 ET Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Nov 10, 2020, 16:05 ET Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Nov 05, 2020, 16:05 ET Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Sep 28, 2020, 16:05 ET Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Sep 14, 2020, 16:05 ET Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Sep 08, 2020, 08:00 ET Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Sep 03, 2020, 16:05 ET Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Aug 10, 2020, 16:05 ET Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jul 27, 2020, 08:00 ET Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jun 16, 2020, 16:01 ET Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Jun 11, 2020, 20:54 ET Avidity Biosciences Announces Pricing of Initial Public Offering

Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

May 19, 2020, 08:00 ET Avidity Biosciences Appoints Michael MacLean as Chief Financial Officer

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the ...

Apr 13, 2020, 08:00 ET Avidity Biosciences Appoints Carsten Boess to its Board of Directors

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the ...

Feb 24, 2020, 16:05 ET Avidity Biosciences Announces Presentations at Upcoming Investor Conferences

Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that...

Feb 12, 2020, 08:00 ET Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer

Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today...

Jan 07, 2020, 16:05 ET Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

Avidity Biosciences (Avidity) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16,...

Oct 01, 2019, 07:30 ET Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer

Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment...

Sep 12, 2019, 08:00 ET Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A....